High-density lipoprotein stimulates myocardial perfusion in vivo

Circulation

Volumn 110, Issue 21, 2004, Pages 3355-3359

  Levkau, Bodo ^a,b   Hermann, Sven ^b   Theilmeier, Gregor ^b   Van Der Giet, Markus ^c   Chun, Jerold ^d   Schober, Otmar ^b   Schäfers, Michael ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Blood flow; Lipoproteins; Microcirculation; Perfusion; Radioisotopes

Indexed keywords

G PROTEIN COUPLED RECEPTOR; HIGH DENSITY LIPOPROTEIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHENYLEPHRINE; SPHINGOSINE 1 PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY RISK; DRUG UPTAKE; HEART MUSCLE PERFUSION; HEART RATE; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VASODILATATION;

ANIMALS; BLOOD PRESSURE; CORONARY CIRCULATION; HEART; HEART RATE; HUMANS; LIPOPROTEINS, HDL; LYSOPHOSPHOLIPIDS; MICE; MICE, KNOCKOUT; MYOCARDIUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; ORGAN SIZE; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; TECHNETIUM TC 99M SESTAMIBI;

EID: 9344262922     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000147827.43912.AE     Document Type: Article

References (27)

1. Rubins HB, Robins SJ, Collins D, et al, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.
2. O'Connell BJ, Genest J Jr. High-density lipoproteins and endothelial function. Circulation. 2001;104:1978-1983.
3. Yuhanna IS, Zhu Y, Cox BE, et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med. 2001;7:853-857.
4. Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399-1402.
5. Gödecke A, Decking UK, Ding Z, et al. Coronary hemodynamics in endothelial NO synthase knockout mice. Circ Res. 1998;82:186-194.
6. Ishii I, Friedman B, Ye XQ, et al. Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LPB3/EDG-3. J Biol Chem. 2001;276:33697-33704.
7. Ishii I, Ye X, Friedman B, et al. Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate receptors, S1P2/LPB2/EDG-5 and S1P3/LPB3/EDG-3. J Biol Chem. 2002;277:25152-25159.
8. 18F-FDG uptake in a transgenic mouse model of stunned myocardium. Eur J Nucl Med Mol Imaging. 2003;30:431-439.
9. Inubushi M, Jordan MC, Roos KP, et al. Nitrogen-13 ammonia cardiac positron emission tomography in mice: effects of clonidine-induced changes in cardiac work on myocardial perfusion. Eur J Nucl Med Mol Imaging. 2004;31:110-116.
10. Havel RJ, Eder H, Bragdon J. The distribution and chemical composition of ultracentrifugally isolated lipoproteins from human plasma. J Clin Invest. 1995;3:1345-1353.
11. Mineo C, Yuhanna IS, Quon MJ, et al. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem. 2003;278:9142-9149.
12. Sugiyama A, Yatomi Y, Ozaki Y, et al. Sphingosine 1-phosphate induces sinus tachycardia and coronary vasoconstriction in the canine heart. Cardiovasc Res. 2000;46:119-125.
13. Richard V, Berdeaux A, la Rochelle CD, et al. Regional coronary haemodynamic effects of two inhibitors of nitric oxide synthesis in anaesthetized, open-chest dogs. Br J Pharmacol. 1991;104:59-64.
14. 3. J Clin Invest. 2004;113:569-581.
15. Yang AH, Ishii I, Chun J. In vivo roles of lysophospholipid receptors revealed by gene targeting studies in mice. Biochim Biophys Acta. 2002;1582:197-203.
16. Fukushima N, Ishii I, Contos JA, et al. Lysophospholipid receptors. Ann Rev Pharmacol Toxicol 2001;41:507-534.
17. Ishii I, Fukushima N, Ye X, et al. Lysophospholipid receptors: signaling and biology. Ann Rev Kochern. 2004;73:321-354.
18. Nofer JR, Kehrel B, Fobker M, et al. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis. 2002;161:1-16.
19. Bischoff A, Czyborra P, Fetscher C, et al. Sphingosine-1-phosphate and sphingosylphosphorylcholine constrict renal and mesenteric microvessels in vitro. Br J Pharmacol. 2000;130:1871-1877.
20. Salomone S, Yoshimura S, Reuter U, et al. S1P(3) receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate. Eur J Pharmacol. 2003;469:125-134.
21. Dantas AP, Igarashi J, Michel T. Sphingosine 1-phosphate and control of vascular tone. Am J Physiol. 2003;284:H2045-H2052.
22. Bolz SS, Vogel L, Sollinger D, et al. Sphingosine kinase modulates microvascular tone and myogenic responses through activation of RhoA/Rho kinase. Circulation. 2003;108:342-347.
23. Glover DK, Ruiz M, Edwards NC, et al. Comparison between 201T1 and 99mTc sestamibi uptake during adenosine-induced vasodilation as a function of coronary stenosis severity. Circulation. 1995;9:813-820.
24. Schelbert HR, Phelps ME, Hoffman EJ, et al. Regional myocardial perfusion assessed with N-13 labeled ammonia and positron emission computerized axial tomography. Am J Cardiol. 1979;43:209-218.
25. Waller C, Kahler E, Hiller KH, et al. Myocardial perfusion and intracapillary blood volume in rats at rest and with coronary dilatation: MR imaging in vivo with use of a spin-labeling technique. Radiology. 2000;215:189-197.
26. Hla T. Signaling and biological actions of sphingosine 1-phosphate. Pharmacol Res. 2003;47:401-407.
27. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003;4:397-407.